Carna Biosciences (TSE:4572) ROCE %: 0.00% (As of Dec. 2025)


TSE:4572 Carna Biosciences Inc TSE:4572
29 GF Score
Price 円314.00
GF Value 円175.60
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Carna Biosciences ROCE %?

Carna Biosciences TSE:4572 -3.68% 29 ROCE % is 0.00% as of Dec. 2025. GuruFocus rates TSE:4572 with a GF Score™ of 29/100 and a GF Value™ of 円175.60 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Carna Biosciences's annualized ROCE % for the quarter that ended in Dec. 2025 was 0.00%.

Carna Biosciences  (TSE:4572) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Carna Biosciences ROCE % Related Terms

Carna Biosciences ROCE % Historical Data

* Premium members only.

The historical data trend for Carna Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carna Biosciences ROCE % Chart

Carna Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.06 -31.06 -28.89 -66.56 -119.63

Carna Biosciences Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -87.24 -128.07 0.00 -127.07
TSE:4572
29GF Score
Carna Biosciences Inc TSE:4572
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carna Biosciences ROCE % Calculation

Carna Biosciences's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-2159.795/( ( (2772.115 - 222.965) + (1229.648 - 168.07) )/ 2 )
=-2159.795/( (2549.15+1061.578)/ 2 )
=-2159.795/1805.364
=-119.63 %

Carna Biosciences's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=0/( ( (1635.585 - 184.225) + (1229.648 - 168.07) )/ 2 )
=0/( ( 1451.36 + 1061.578 )/ 2 )
=0/1256.469
=0.00 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Carna Biosciences (TSE:4572) has a ROCE % of 0.00% as of Dec. 2025.
Is Carna Biosciences' ROCE % too high?
Carna Biosciences' current ROCE % is 0.00%. Overall, Carna Biosciences has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Carna Biosciences' ROCE % compare to VRTX and REGN?
Carna Biosciences' ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Carna Biosciences's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carna Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Carna Biosciences (TSE:4572) is currently considered Significantly Overvalued. The stock's GF Value™ is 円175.60, compared to a current price of 円314.00 — trading 78.8% above its estimated fair value. The current ROCE % is 0.00%. Carna Biosciences' overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Carna Biosciences (TSE:4572), the current ROCE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carna Biosciences (TSE:4572) Overvalued in 2026?

Based on GuruFocus' analysis, Carna Biosciences stock appears to be overvalued. The current stock price of 円314.00 is trading 78.8% above its estimated GF Value™ of 円175.60. GuruFocus considers Carna Biosciences to be Significantly Overvalued.

Key valuation signals for TSE:4572:

  • ROCE %: 0.00%
  • GF Value™: 円175.60 vs. price of 円314.00 (78.8% above fair value)
  • GF Score™: 29/100 with 6 warning signs

No single metric tells the full story. See the TSE:4572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carna Biosciences Business Description

Address BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047
Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.
29GF Score

Get the complete analysis for TSE:4572

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円314.00
Price
円175.60
GF Value